DISEASE INDICATIONS: Lung Cancer

MANUFACTURER: Eli Lilly Nederland B.V.

USAGE: Intravenous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Portrazza (necitumumab) is a medication approved for the treatment of advanced squamous non-small cell lung cancer. It is used in combination with the chemotherapies gemcitabine and cisplatin.